GILD - Gilead Sciences, Inc.
80.15 +0.14 (0.17%)
After hours: 4:36PM EDT
| Previous Close | 80.24 |
| Open | 80.26 |
| Bid | 79.81 x 100 |
| Ask | 80.25 x 400 |
| Day's Range | 79.76 - 80.84 |
| 52 Week Range | 63.76 - 86.27 |
| Volume | 5,945,247 |
| Avg. Volume | 9,306,200 |
| Market Cap | 104.49B |
| Beta | 0.90 |
| PE Ratio (TTM) | 8.69 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.08 (2.56%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
- Market Realist•6 hours ago
Inside Gilead’s HBV Portfolio Performance in 1H17
In 1H17, Gilead Sciences' (GILD) Viread generated revenues of ~$560 million, compared with $559 in 1H16.
- Market Realist•8 hours ago
How Gilead’s HCV Drug Portfolio Is Positioned after 1H17
In 1H17, Gilead Sciences’ (GILD) Harvoni reported revenues of ~$2.75 billion, compared with $5.58 billion in 1H16.
Markit•9 hours agoSee what the IHS Markit Score report has to say about Gilead Sciences Inc.
Gilead Sciences Inc NASDAQ/NGS:GILD
- Zacks•21 hours ago
Where to Find Value in Healthcare Stocks
The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.
- Motley Fool•23 hours ago
Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics
Both of these small-cap biotechs are advancing new cancer therapies, but which stock is the best pick right now?
- Market Realist•yesterday
US Pharma Mergers and Acquisitions in 3Q17
Calendar 3Q17 saw several major mergers and acquisitions in the US pharmaceutical industry.
- Zacks•yesterday
Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
- Market Realist•yesterday
This Could Really Drive Gilead’s Revenue Growth in 2018
FDA approval of BIC/FTC/TAF is expected to strengthen Gilead Sciences’ HIV franchise.
- Zacks•yesterday
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
- Market Realist•yesterday
How Gilead Sciences Is Positioned after 1H17
In 1H17, Gilead Sciences (GILD) reported revenues of ~$13.4 billion, compared with to $15.6 billion in 1H16.
- Market Realist•yesterday
Gilead Sciences on the Street: Analyst Recommendations in October
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."
- Barrons.com•2 days ago
[$$] More Biotechs That Can Beat Q3 Views
Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates. Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website.
- Forbes•2 days ago
Berkshire Hathaway And 6 Other Piggyback Stocks To Profit From
Seven buy list stocks from some of the greatest value investors.
- Zacks•2 days ago
The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon
The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon
- Investor's Business Daily•2 days ago
6 Top Biotech Companies In Innovation Earn Recognition In New Awards
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
- Investor's Business Daily•2 days ago
Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field
Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.
- The Wall Street Journal•3 days ago
[$$] Nimbus Therapeutics Strikes Immunology Deal With Celgene
Nimbus Therapeutics, which struck a $1.2 billion deal to sell a drug program focused on liver diseases to Gilead Sciences Inc. last year, has formed a new immunology collaboration with Celgene Corp.
- Zacks•5 days ago
Top Stock Reports for NIKE, Cisco Systems & Gilead Sciences
Top Stock Reports for NIKE, Cisco Systems & Gilead Sciences
- InvestorPlace•5 days ago
It’s Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock
Then there was the demise of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), followed by an EpiPen scandal at Mylan N.V. (NASDAQ:MYL). While GILD stock also fell, the reasons were largely unrelated to the scandals which plagued its peers. The company’s big Hepatitis C Virus (HCV) drug worked really well.
- InvestorPlace•5 days ago
Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.
- Motley Fool•5 days ago
3 Healthcare Value Stocks
Looking for some investments in the healthcare sector that aren't priced at a high premium? Allergan, Gilead Sciences, and DaVita are an excellent place to start.
- Zacks•6 days ago
Non-Alcoholic Steatohepatitis 2017 Progress Update
Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).
- Investopedia•6 days ago
Top 5 Biotech Stocks for 2017
Biotech can be risky, but these top biotech stocks have stable track records.
- Investopedia•6 days ago
Celgene, Biogen Are Poised to Break Out: A Technical View
After a period of consolidation, the biotech sector is set to rise again based on technical analysis.
- Motley Fool•6 days ago
5 Game-Changing Cancer Drug Innovations Being Developed Right Now
Could these revolutionary therapies turn the tide in the fight against cancer?
